Industrials
MindMaze Therapeutics Holding S.A. Sponsored ADR(RLFTY)
Live Price
Offline$0.4225
+0.00% today
1Y Change
-85.92%
Window
Jun 20, 2025 β Jun 17, 2026
- Market Cap
- β
- Revenue Growth
- -92.4%
- EPS Growth
- +42.3%
- Dividend Yield
- 0.0%
Coverage: 249 bars Β· Jun 20, 2025 β Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
MindMaze Therapeutics Holding S.A. Sponsored ADR (RLFTY) is a Industrials stock with listed on OTC. The stock last traded around $0.42 and down 85.9% across the available one-year price window (Jun 20, 2025 β Jun 17, 2026). Baseline metrics include revenue growth of -92.4%, EPS growth of +42.3%, a dividend yield of 0.0%. What stands out right now is revenue -92.4%, EPS +42.3%, free cash flow -134.1% with operating margin 0.0% and ROIC 0.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RLFTY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Industrials peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-92.4% vs +3.6% peer median
Operating Margin
Below sector median
0.0% vs +16.9% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 8, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -92.4% and EPS is at +42.3%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.2% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 8, 2026 | β | +0.0% | +2.1% | -88.4% |
2025 Sep 1, 2025 | β | +0.0% | -0.6% | +25.5% |
2025 Apr 10, 2025 | β | +0.0% | -1.0% | +3.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RLFTY
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
RLFTY Max Drawdown
-94.43%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RLFTY and SPY.
Company Overview
MindMaze Therapeutics Holding S.A. Sponsored ADR
Other OTC
MindMaze Therapeutics Holding SA engages in the development of AI-powered neurotherapeutics and pharmacological treatments for brain disorders. It focuses on addressing neurological and neuropsychiatric conditions through advanced research, clinical development, and technology-driven solutions. The company is headquartered in Geneva, Switzerland.
- Leadership
- Zach W. Henderson
- IPO Date
- Nov 23, 2021
- Employees
- 31
- Street Address
- BΓ’timent F2/F3
- Mailing
- Geneva, 1202
- Region
- Geneva, CH
- Reporting Currency
- USD
- Investor Line
- +41 21 552 08 01
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- β
- Price/Book
- β
Growth
- Revenue
- -92.4%
- EPS
- +42.3%
- Free Cash Flow
- -134.1%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 0.0%
- ROIC
- 0.0%
Balance Sheet
- Debt/Equity
- β
- Current Ratio
- β
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.